BAY R3401
BAY R3401 is an orally active glycogen phosphorylase inhibitor that can achieve irreversible and non-selective inhibition of hepatic glycogenolysis. BAY R3401 inhibits glycogenolysis in liver cells, with IC50 values of 27.06 and 52.83 μM in HL-7702 and HepG2 cells, respectively. BAY R3401 can be used for the research of type 2 diabetes[1].
Product Specifications
CAS Number
100276-03-7
UNSPSC
12352005
Hazard Statement
H302
Target
Phosphorylase
Related Pathways
Metabolic Enzyme/Protease
Field of Research
Metabolic Disease
Smiles
O=C(C1=C(C)N(CC)C(COC2=O)=C2C1C3=CC=CC=C3Cl)OC(C)C
Molecular Formula
C20H22ClNO4
Molecular Weight
375.85
Precautions
P264-P270-P330-P501
References & Citations
[1]Zhang L, et al. Design, Synthesis, and Biological Application of Novel Photoaffinity Probes of Dihydropyridine Derivatives, BAY R3401. Molecules. 2019 Jun 28;24 (13) :2394.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
